Related Experiment Video
Updated: Oct 8, 2025
Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
Published on: March 4, 2014
[Early diagnosis of spinal muscular atrophy]
Alfred Peter Born1, Ulla Werlauff
1alfred.peter.born@regionh.dk.
Insights
Early diagnosis and treatment are crucial for spinal muscular atrophy (SMA) in children. Disease-modifying drugs show the most benefit in young, pre-symptomatic individuals, highlighting the need for increased awareness and screening.
Area of Science:
- Pediatric neurology
- Genetics
- Clinical pharmacology
Background:
- Spinal muscular atrophy (SMA) is a genetic disorder leading to progressive motor neuron degeneration.
- Untreated SMA results in significant motor impairment in children.
- Current treatments offer the greatest benefit when initiated early.
Purpose of the Study:
- To review the efficacy of disease-modifying drugs for spinal muscular atrophy (SMA).
- To emphasize the importance of early diagnosis and treatment in pediatric SMA cases.
- To discuss the implications of neonatal screening for SMA.
Main Methods:
- Literature review of clinical trials for SMA treatments.
- Analysis of treatment outcomes based on patient age and symptom presentation.
- Discussion of current diagnostic and screening practices for SMA.
Main Results:
- Disease-modifying drugs for SMA demonstrate maximal efficacy in young and pre-symptomatic children.
- Delayed diagnosis and treatment negatively impact outcomes in pediatric SMA.
- Neonatal screening for SMA is under consideration in Denmark.
Conclusions:
- Early intervention is critical for improving outcomes in spinal muscular atrophy.
- Increased medical staff awareness and accessible information for families can reduce diagnostic delays.
- Implementation of neonatal screening programs is essential for timely SMA management.
Abstract:
Untreated spinal muscular atrophy (SMA) causes progressive motor impairment in affected children. Clinical trials of newly developed disease-modifying drugs have shown the greatest effect in young and in pre-symptomatic children as summarised in this review. An application for neonatal screening in Denmark is currently under consideration. Diagnosis and treatment of children with SMA is often delayed, and until a national screening becomes available, the only way to reduce diagnostic delay is to increase the awareness of medical staff and to make information on early signs of SMA available for concerned families.
More Related Videos
12:35Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
Published on: March 17, 2012
09:07Electrophysiological Motor Unit Number Estimation MUNE Measuring Compound Muscle Action Potential CMAP in Mouse Hindlimb Muscles
Published on: September 25, 2015
Related Concept Videos
01:15Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:21Satellite Stem Cells and Muscular Dystrophy
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...